News Archive

September 2015

• 
  Story Sep 18, 2015 Access to Healthcare

  Confronting the global spread of chronic disease

  Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.

• Press Release Sep 18, 2015

  Swissmedic approves Novartis' new heart failure medicine Entresto(TM)

  Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities…
• 
  Story Sep 10, 2015 Access to Healthcare

  Malaria fighter rides bicycle into battle with disease

  Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.

• 
  Story Sep 08, 2015 Patient Perspectives

  Putting patients first

  Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.

• Press Release Sep 07, 2015

  Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH

  Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients  Retrospective contact tracing of former leprosy…
• Press Release Sep 04, 2015

  Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma

  Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
• Press Release Sep 03, 2015

  Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States

  Launch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here:   Holzkirchen,…
• Press Release Sep 02, 2015

  Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia

  Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments  Patients living with SAA, a rare blood disorder,…
• Press Release Sep 01, 2015

  Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments

  The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule  Novartis and Amgen also plan…
• Press Release Sep 01, 2015

  Novartis setzt sich weiter für die endgültige Ausrottung von Lepra ein

  Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden…
• Press Release Sep 01, 2015

  Novartis renouvelle son engagement à l'approche de la dernière ligne droite dans la lutte visant à éradiquer la lèpre

  Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau…
• Press Release Sep 01, 2015

  Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma

  Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy  Targeted combination offers…